News and Trends 6 Jul 2017 Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II Prothena and Roche are advancing their Parkinson’s antibody to Phase II, triggering a new milestone payment from what is proving a lucrative deal for Prothena. Prothena, the largest biopharma in Ireland, and its partner Roche have announced the first patient has been enrolled in a Phase II trial testing an antibody treatment for Parkinson’s. Reaching […] July 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2017 Results are in from the First Human Trial of an Universal Cancer Vaccine BioNTech has published results from the first clinical trial for an mRNA-based individualized vaccine with the potential to target all cancer types. Published in Nature, the results from the first trial in humans with a personalized mRNA cancer vaccine hint that BioNTech is on a promising track towards the development of a universal cancer vaccine. All […] July 5, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2017 Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in […] July 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2017 Cutting Through the BS in Biopharma: How To Spot Hype Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can patients, investors, and readers be spared more disappointment? After discussing failures in biotech at Refresh earlier in June, I headed to Copenhagen last week for the European Conference for Science Journalists to cajole a panel into discussing how some of these stories feature […] July 5, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2017 British Liquid Biopsy for Ovarian Cancer Outperforms the Gold Standard The British company Angle has announced results from a large-scale trial that seem to indicate its liquid biopsy technology could surpass the gold standard in ovarian cancer diagnosis. Angle, in the UK, is developing liquid biopsy tests to replace biopsies in the diagnosis of cancer. The company has announced results from a 400-patient trial in […] July 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2017 From Rockets to DNA – From SpaceX to CRISPR With CRISPR being one of the most significant discoveries in genome engineering history, many scientists are now turning towards it as a basic foundation of their research. In response, companies are developing new technologies and products designed to help these very scientists become more effective in their research. One such company is Silicon Valley entity […] July 3, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 3 Jul 2017 Video: Is mRNA a True Game-Changer? Fireside Chat with Sean Marett, COO of BioNTech Sean Marett took a red-eye from New York to speak at Refresh last month: here are his thoughts on how mRNA therapeutics are taking biotech by storm! mRNA has become one of the next big things in biotech, and Germany-based BioNTech is at the forefront of the wave, developing personalized treatments for cancer. “We try to provide individualized […] July 3, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2017 Scottish AI Biotech Recruits Another Pharma Partner in €37M Deal After Sanofi recruited Exscientia in a €250M deal last May, GSK has taken an interest in the startup and invested in a collaboration of its own. Artificial intelligence has been carving out a niche for itself in biotech, and Exscientia is fast establishing itself as a key player in the field. In May, the company signed a […] July 3, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 3 Jul 2017 These Norwegian Biotech Execs are Bringing Back Cancer Vaccines & Oncolytic Viruses We talked to CEO Øystein Soug and CMO Magnus Jäderberg of Targovax about why the company’s technologies may succeed where others have failed. In 2010, Targovax rose from the ashes of Norsk Hydro Pharma, the discontinued therapeutic development arm of the conglomerate. The Oslo-based biotech is taking a stand against tough-to-treat cancers like that of […] July 3, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2017 Quantum Worms from London win the Biodesign Challenge 2017 A team of students from Central Saint Martins, London, has won this year’s biodesign challenge with a project in which worms turn into tech factories. Every year, teams working at the intersection of biology and design compete to win the Biodesign Challenge held at the famous New York City’s Museum of Modern Art (MoMA). This year’s edition […] July 1, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2017 Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy based on off-the-shelf mRNA technology. eTheRNA is one of the few companies working in mRNA therapies that are running clinical trials. The Belgian biotech has announced the start of a Phase Ib trial with its candidate TriMix-MEL, also called ECI-006, in patients […] June 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2017 €40M in Series C for a British Biotech Treating Blindness with Gene Therapy NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the market, the company has closed a Series C round with $45M (€39.5M) […] June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email